CAR T cell therapy leads to 10-year remissions in B-cell lymphoma patients
After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel—the CAR T-cell therapy ...
Jun 25, 2026
0
6









